NSE: GRANULES | BSE: 532482

Mid-range Performer

Download real time

517.95 1.75 (0.34%)

28.16% Fall from 52W High

482.3K NSE+BSE Volume

NSE 23 May, 2025 3:31 PM (IST)

12,562.6

Market Cap

High in industry

1.1

Beta 1Year

High Volatility

Board Meeting

The next board meeting for Granules India Ltd. is on 28 May 2025 for the purpose of Audited Results & Final Dividend See details

Granules India Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for GRANULES, BSE:532482 Granules India Ltd.

Granules India Ltd.

31 Jan 2019

517.95

0.34%

BP Equities Granules India Ltd Q3FY19 Result Upda

Buy: Granules India Ltd.

Target

BP Wealth

Granules India Ltd. is trading below its 150 day SMA of 535.9

Granules India Ltd.

02 Nov 2018

517.95

0.34%

GRANULES INDIA

Buy: Granules India Ltd.

Recommendation Target

Geojit BNP Paribas

Higher API and FD sales drove the numbers Granules (Inc) is a leading generic player in the Indian pharmaceutical industry with 2/3rd of its revenue generated from North America and Europe and the rest accomplished from Emerging markets like India. Q2FY19 revenue grew by 47% YoY driven by higher sales in API...

Granules India Ltd. is trading below its 150 day SMA of 535.9

Granules India Ltd.

31 Oct 2018

517.95

0.34%

Granules India (2QFY19): Delivery started. Maintain BUY

Buy: Granules India Ltd.

Target

HDFC Securities

At CMP, the stock is trading at 18.6x FY18, 11.6x FY19E and 9.2x FY20E EPS, still 50% cheaper to industry peers. Maintain BUY with a TP of Rs 140 (12x Sep'20E EPS). Continuing the momentum post sequential recovery in the previous quarter, Granules (GRAN) reported strong double-digit growth with revenue at Rs 5.8bn (+48/28% YoY/QoQ) in 2QFY19. This was driven by the API and FDF segments, and three product launches in the US market (gMethergine, Methocarbamol and Metformin XR). EBITDA came in at Rs 1bn with margin at 17.3% (down 230bps YoY/ up 130bps QoQ).

Granules India Ltd. is trading below its 150 day SMA of 535.9

Granules India Ltd.

31 Oct 2018

517.95

0.34%

BP Equities Granules Pharma Ltd Q2FY19 Result Upd

Buy: Granules India Ltd.

Target

BP Wealth

Granules India Ltd. is trading below its 150 day SMA of 535.9

Granules India Ltd.

25 Jul 2018

517.95

0.34%

Granules India (1QFY19): Recovery in sight. Maintain BUY

Buy: Granules India Ltd.

Target

HDFC Securities

We continue to maintain BUY with a TP of Rs 120 (12x FY20E). Continued growth in API and Formulations coupled with the launch of gMethergine led to 20%YoY growth in revenue, coming up to Rs 4.5bn for 1QFY19. The absence of inventory write-off and one-off R&D; which were seen last quarter along with improved raw material pricing resulted into a 700bps QoQ jump in EBITDA margin to 16%. Other Income was up 52%QoQ largely driven by forex gain to the tune of Rs 110mn.

Granules India Ltd. is trading below its 150 day SMA of 535.9

Granules India Ltd.

25 Jul 2018

517.95

0.34%

The impact of Raw Material (RM) inflation is waning as Granules India (GRAN) pushes for c...

Results Update: Granules India Ltd.

Emkay

for FY19 means there could be upside risk to our estimates. Extensive capex cycle is nearing an end with asset turnover expected to head higher over the next 2 years with the full impact of capacity commissioning seen in FY20. We largely maintain estimates with FY18-20E EPS CAGR seen at 40%. We maintain our...

Granules India Ltd. has an average target of 682.00 from 5 brokers.

Granules India Ltd.

25 Jul 2018

517.95

0.34%

GRANULES INDIA

Accumulate: Granules India Ltd.

Geojit Research

Granules (Inc) is a leading generic player in the Indian pharmaceutical industry with a 2/3rd of its revenue generated from North America and Europe and the rest accomplished from Emerging markets like India. Q1FY19 revenue grew by 18% YoY due to better performance from enhanced plant capacities and stronger domestic performance. EBITDA registered a 13% growth YoY while margin declined by 300bps to 16.8% on account of higher raw material cost (RM). PAT is up by 23% YoY due to higher other income and Joint venture...

Granules India Ltd. is trading below its 150 day SMA of 535.9

Granules India Ltd.

30 May 2018

517.95

0.34%

Granules India

Buy: Granules India Ltd.

Geojit BNP Paribas

Granules (Inc) is a leading generic player in the Indian pharmaceutical industry with a 2/3rd of its revenue generated from North America and Europe and the rest coming from Emerging markets like India. Q4FY18 revenue grew significantly by 39% YoY on incremental sales from newly added capacities while PAT de-grew by 55% on account of higher raw material (RM) cost and one time inventory write off....

Granules India Ltd. is trading below its 150 day SMA of 535.9

Granules India Ltd.

28 May 2018

517.95

0.34%

Raw Material (RM) cost inflation a spoiler for what could have been a strong quarter for...

Buy: Granules India Ltd.

Target

Emkay

Manufacturing cost adversely impacted by transient and non-transient factors RM cost for GRAN spiked due to a combination of supply disruptions for a key ingredient (fire at supplier's factory), higher crude and plant closures in China impacting ingredient supplies. Some of the factors are likely to prove transient, but complete gross margins recovery unlikely any time in the near/medium term. Timing difference means GRAN unlikely to be able to fully pass on cost inflation GRAN has automatic pricing resets for ~50% of its ongoing supplies, but for the balance supplies it has to negotiate with customers. The risk here is that if the price appreciation is...

Granules India Ltd. is trading below its 150 day SMA of 535.9

Granules India Ltd.

25 May 2018

517.95

0.34%

Granules India (4QFY18): Aberrant quarter. Maintain BUY

Buy: Granules India Ltd.

Target

HDFC Securities

We continue to maintain BUY with reduced TP of Rs 115 (12x FY20E). Driven by fresh capacities in API/PFI and resumption of OTC product supplies for the US partner, revenues grew 42%YoY to Rs 5.0bn in 4QFY18. However, steep price increase in key raw materials (ex. Acetic acetate), unfavorable geographic mix and inventory write off led to sharp fall in EBITDA margin from 18% in 3QFY18 to 8.7% in 4QFY18. As a result, reported PAT was at Rs 204mn, down 55%YoY.

Granules India Ltd. has an average target of 682.00 from 5 brokers.

Is Granules India Ltd. worth buying?

859 Votes:

Buy 84.05%

Sell 10.24%

Hold 5.7%

RESEARCH REPORTS

Accumulate SEE REPORTS >

pdf

Buy SEE REPORTS >

pdf